Nonmelanoma skin cancer.
This article provides readers with a comprehensive review of the evaluation and management of nonmelanoma skin cancers. Treatment recommendations are heavily based on the most recent guidelines from the National Comprehensive Cancer Network. Merkel cell carcinoma and dermatofibrosarcoma protuberans are also discussed. After reviewing this article, readers should be equipped with a better understanding of these entities and the current recommendations for their management.
Lee
David A
DA
Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Miller
Stanley J
SJ
D001707:Biopsy, Needle; D015266:Carcinoma, Merkel Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003452:Cryosurgery; D018223:Dermatofibrosarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005153:Facial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D055623:Keratosis, Actinic / Q000401:mortality / Q000473:pathology / Q000628:therapy; D053685:Laser Therapy / Q000379:methods; D008297:Male; D015580:Mohs Surgery / Q000379:methods; D009364:Neoplasm Recurrence, Local / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011701:PUVA Therapy; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016019:Survival Analysis